info@seagull-health.com
SeagullHealth
search
Duvyzat(Givinostat)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Duvyzat(Givinostat) Instructions:Uses,Dosage, Side Effects
DUVYZAT (givinostat) is a histone deacetylase inhibitor approved for treating Duchenne muscular dystrophy (DMD) in patients aged 6 years and older. It modulates gene expression, potentially slowing disease progression by reducing muscle degeneration. The drug is administered orally as a weight-based suspension twice daily with food. Key safety considerations include monitoring for thrombocytopenia, hypertriglyceridemia, and QTc prolongation.
Clinical trials demonstrated efficacy in delaying functional decline, with a 1.78-second improvement in 4-stair climb time versus placebo over 18 months. Common adverse reactions include diarrhea, abdominal pain, and hematological changes. DUVYZAT requires rigorous adherence to dosing guidelines and regular laboratory monitoring to mitigate risks.
DUVYZAT is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.
The recommended dosage of DUVYZAT is based on body weight and administered orally twice daily with food:
10 kg to less than 20 kg: 22.2 mg (2.5 mL) twice daily;
20 kg to less than 40 kg: 31 mg (3.5 mL) twice daily;
40 kg to less than 60 kg: 44.3 mg (5 mL) twice daily;
60 kg or more: 53.2 mg (6 mL) twice daily.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
